Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age.
The worldwide elimination of measles is an important target. In developed countries, to control measles outbreaks, immunization from 6 months of age is recommended. In this study, infants (n = 290) who were (1) born to mothers with natural immunity or to vaccinated mothers and (2) previously immunized with Connaught (CLL) or AIK-C measles vaccine at 6 months of age, were evaluated for measles immunity before and after measles-mumps-rubella (MMRII at 15 months of age. Eight weeks after MMRII, 98.9% of infants were seropositive by enzyme immunoassay (EIA) and 70% demonstrated measles specific cellular immunity by blast transformation (BT) of lymphocytes. At 27 months of age, 98.4% of infants had protective antibody levels by plaque reduction neutralization (PRN) test. These results suggest that AIK-C and CLL vaccines elicit durable protective immunity in young infants when used in early immunization programs.
Carson
Mary M
MM
Department of Pediatrics, University of Alberta, Edmonton, Canada. mcarson@cha.ab.ca
Spady
Donald W
DW
Beeler
Judith A
JA
Krezolek
Margaret P
MP
Audet
Susette
S
Pabst
Henry F
HF
D000375:Aging / Q000276:immunology; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis*; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007115:Immunization Schedule; D007124:Immunoenzyme Techniques; D007223:Infant; D008213:Lymphocyte Activation; D008297:Male; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D009500:Neutralization Tests
D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine